dc.date.accessioned | 2022-11-10T17:41:10Z | |
dc.date.available | 2022-11-10T17:41:10Z | |
dc.date.created | 2022-06-03T13:25:10Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Anda, Erik Eik Braaten, Tonje Bjørndal Borch, Kristin Benjaminsen Nøst, Therese Haugdahl Chen, Sairah Lai Fa Lukic, Marko Lund, Eiliv Forland, Frode Leon, David Andrew Askeland Winje, Brita Kran, Anne-Marte Bakken Kalager, Mette Lund-Johansen, Fridtjof Sandanger, Torkjel M . Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21. Eurosurveillance. 2022, 27):pii=2100376(13), 1-10 | |
dc.identifier.uri | http://hdl.handle.net/10852/97547 | |
dc.description.abstract | Background
Since March 2020, 440 million people worldwide have been diagnosed with COVID-19, but the true number of infections with SARS-CoV-2 is higher. SARS-CoV-2 antibody seroprevalence can add crucial epidemiological information about population infection dynamics.
Aim
To provide a large population-based SARS-CoV-2 seroprevalence survey from Norway; we estimated SARS-CoV-2 seroprevalence before introduction of vaccines and described its distribution across demographic groups.
Methods
In this population-based cross-sectional study, a total of 110,000 people aged 16 years or older were randomly selected during November–December 2020 and invited to complete a questionnaire and provide a dried blood spot (DBS) sample.
Results
The response rate was 30% (31,458/104,637); compliance rate for return of DBS samples was 88% (27,700/31,458). National weighted and adjusted seroprevalence was 0.9% (95% CI (confidence interval): 0.7–1.0). Seroprevalence was highest among those aged 16–19 years (1.9%; 95% CI: 0.9–2.9), those born outside the Nordic countries 1.4% (95% CI: 1.0–1.9), and in the counties of Oslo 1.7% (95% CI: 1.2–2.2) and Vestland 1.4% (95% CI: 0.9–1.8). The ratio of SARS-CoV-2 seroprevalence (0.9%) to cumulative incidence of virologically detected cases by mid-December 2020 (0.8%) was slightly above one. SARS-CoV-2 seroprevalence was low before introduction of vaccines in Norway and was comparable to virologically detected cases, indicating that most cases in the first 10 months of the pandemic were detected.
Conclusion
Findings suggest that preventive measures including contact tracing have been effective, people complied with physical distancing recommendations, and local efforts to contain outbreaks have been essential. | |
dc.language | EN | |
dc.publisher | European Centre for Disease Prevention and Control | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21 | |
dc.title.alternative | ENEngelskEnglishSeroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21 | |
dc.type | Journal article | |
dc.creator.author | Anda, Erik Eik | |
dc.creator.author | Braaten, Tonje Bjørndal | |
dc.creator.author | Borch, Kristin Benjaminsen | |
dc.creator.author | Nøst, Therese Haugdahl | |
dc.creator.author | Chen, Sairah Lai Fa | |
dc.creator.author | Lukic, Marko | |
dc.creator.author | Lund, Eiliv | |
dc.creator.author | Forland, Frode | |
dc.creator.author | Leon, David Andrew | |
dc.creator.author | Askeland Winje, Brita | |
dc.creator.author | Kran, Anne-Marte Bakken | |
dc.creator.author | Kalager, Mette | |
dc.creator.author | Lund-Johansen, Fridtjof | |
dc.creator.author | Sandanger, Torkjel M | |
cristin.unitcode | 185,52,0,0 | |
cristin.unitname | Institutt for helse og samfunn | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2029379 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Eurosurveillance&rft.volume=27):pii=2100376&rft.spage=1&rft.date=2022 | |
dc.identifier.jtitle | Eurosurveillance | |
dc.identifier.volume | 27 | |
dc.identifier.issue | 13 | |
dc.identifier.startpage | 1 | |
dc.identifier.endpage | 10 | |
dc.identifier.doi | https://doi.org/10.2807/1560-7917.ES.2022.27.13.2100376 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1025-496X | |
dc.type.version | PublishedVersion | |